Impact & blast traumatic brain injury

Implications for therapy

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Traumatic brain injury (TBI) is one of the most frequent causes of combat casualties in Operations Iraqi Freedom (OIF), Enduring Freedom (OEF), and New Dawn (OND). Although less common than combat-related blast exposure, there have been significant numbers of blast injuries in civilian populations in the United States. Current United States Department of Defense (DoD) ICD-9 derived diagnoses of TBI in the DoD Health Care System show that, for 2016, severe and moderate TBIs accounted for just 0.7% and 12.9%, respectively, of the total of 13,634 brain injuries, while mild TBIs (mTBIs) accounted for 86% of the total. Although there is a report that there are differences in the frequency of long-term complications in mTBI between blast and non-blast TBIs, clinical presentation is classified by severity score rather than mechanism because severity scoring is associated with prognosis in clinical practice. Blast TBI (bTBI) is unique in its pathology and mechanism, but there is no treatment specific for bTBIs-these patients are treated similarly to TBIs in general and therapy is tailored on an individual basis. Currently there is no neuroprotective drug recommended by the clinical guidelines based on evidence.

Original languageEnglish (US)
Article number245
JournalMolecules
Volume23
Issue number2
DOIs
StatePublished - Jan 1 2018

Fingerprint

brain damage
blasts
therapy
Brain
2003-2011 Iraq War
combat
United States Department of Defense
Blast Injuries
Neuroprotective Agents
International Classification of Diseases
casualties
Brain Injuries
scoring
prognosis
pathology
Pathology
Therapeutics
Health care
Guidelines
health

Keywords

  • Brain trauma foundation guideline
  • Therapeutic strategy
  • Traumatic brain injury

ASJC Scopus subject areas

  • Organic Chemistry

Cite this

Impact & blast traumatic brain injury : Implications for therapy. / Yamamoto, Satoshi; Dewitt, Douglas; Prough, Donald.

In: Molecules, Vol. 23, No. 2, 245, 01.01.2018.

Research output: Contribution to journalReview article

@article{a2f25888f0264e6cb25d4a55edcc7f9d,
title = "Impact & blast traumatic brain injury: Implications for therapy",
abstract = "Traumatic brain injury (TBI) is one of the most frequent causes of combat casualties in Operations Iraqi Freedom (OIF), Enduring Freedom (OEF), and New Dawn (OND). Although less common than combat-related blast exposure, there have been significant numbers of blast injuries in civilian populations in the United States. Current United States Department of Defense (DoD) ICD-9 derived diagnoses of TBI in the DoD Health Care System show that, for 2016, severe and moderate TBIs accounted for just 0.7{\%} and 12.9{\%}, respectively, of the total of 13,634 brain injuries, while mild TBIs (mTBIs) accounted for 86{\%} of the total. Although there is a report that there are differences in the frequency of long-term complications in mTBI between blast and non-blast TBIs, clinical presentation is classified by severity score rather than mechanism because severity scoring is associated with prognosis in clinical practice. Blast TBI (bTBI) is unique in its pathology and mechanism, but there is no treatment specific for bTBIs-these patients are treated similarly to TBIs in general and therapy is tailored on an individual basis. Currently there is no neuroprotective drug recommended by the clinical guidelines based on evidence.",
keywords = "Brain trauma foundation guideline, Therapeutic strategy, Traumatic brain injury",
author = "Satoshi Yamamoto and Douglas Dewitt and Donald Prough",
year = "2018",
month = "1",
day = "1",
doi = "10.3390/molecules23020245",
language = "English (US)",
volume = "23",
journal = "Molecules",
issn = "1420-3049",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "2",

}

TY - JOUR

T1 - Impact & blast traumatic brain injury

T2 - Implications for therapy

AU - Yamamoto, Satoshi

AU - Dewitt, Douglas

AU - Prough, Donald

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Traumatic brain injury (TBI) is one of the most frequent causes of combat casualties in Operations Iraqi Freedom (OIF), Enduring Freedom (OEF), and New Dawn (OND). Although less common than combat-related blast exposure, there have been significant numbers of blast injuries in civilian populations in the United States. Current United States Department of Defense (DoD) ICD-9 derived diagnoses of TBI in the DoD Health Care System show that, for 2016, severe and moderate TBIs accounted for just 0.7% and 12.9%, respectively, of the total of 13,634 brain injuries, while mild TBIs (mTBIs) accounted for 86% of the total. Although there is a report that there are differences in the frequency of long-term complications in mTBI between blast and non-blast TBIs, clinical presentation is classified by severity score rather than mechanism because severity scoring is associated with prognosis in clinical practice. Blast TBI (bTBI) is unique in its pathology and mechanism, but there is no treatment specific for bTBIs-these patients are treated similarly to TBIs in general and therapy is tailored on an individual basis. Currently there is no neuroprotective drug recommended by the clinical guidelines based on evidence.

AB - Traumatic brain injury (TBI) is one of the most frequent causes of combat casualties in Operations Iraqi Freedom (OIF), Enduring Freedom (OEF), and New Dawn (OND). Although less common than combat-related blast exposure, there have been significant numbers of blast injuries in civilian populations in the United States. Current United States Department of Defense (DoD) ICD-9 derived diagnoses of TBI in the DoD Health Care System show that, for 2016, severe and moderate TBIs accounted for just 0.7% and 12.9%, respectively, of the total of 13,634 brain injuries, while mild TBIs (mTBIs) accounted for 86% of the total. Although there is a report that there are differences in the frequency of long-term complications in mTBI between blast and non-blast TBIs, clinical presentation is classified by severity score rather than mechanism because severity scoring is associated with prognosis in clinical practice. Blast TBI (bTBI) is unique in its pathology and mechanism, but there is no treatment specific for bTBIs-these patients are treated similarly to TBIs in general and therapy is tailored on an individual basis. Currently there is no neuroprotective drug recommended by the clinical guidelines based on evidence.

KW - Brain trauma foundation guideline

KW - Therapeutic strategy

KW - Traumatic brain injury

UR - http://www.scopus.com/inward/record.url?scp=85041221489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041221489&partnerID=8YFLogxK

U2 - 10.3390/molecules23020245

DO - 10.3390/molecules23020245

M3 - Review article

VL - 23

JO - Molecules

JF - Molecules

SN - 1420-3049

IS - 2

M1 - 245

ER -